[go: up one dir, main page]

BR9815395A - Composições à base de nicotina e método de formulção das mesmas - Google Patents

Composições à base de nicotina e método de formulção das mesmas

Info

Publication number
BR9815395A
BR9815395A BR9815395-1A BR9815395A BR9815395A BR 9815395 A BR9815395 A BR 9815395A BR 9815395 A BR9815395 A BR 9815395A BR 9815395 A BR9815395 A BR 9815395A
Authority
BR
Brazil
Prior art keywords
precursors
descendants
liquid crystals
dispersions
nicotine
Prior art date
Application number
BR9815395-1A
Other languages
English (en)
Inventor
Sven Borje Andersson
Stefan Jonn
Tomas Landh
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of BR9815395A publication Critical patent/BR9815395A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<B>"COMPOSIçõES à BASE DE NICOTINA E MéTODOS DE FORMULAçãO DAS MESMAS"<D>. A presente invenção se refere a formulações de nicotina de lipídios polares em cristais líquidos e dispersões coloidais dos mesmos e precursores e descendentes dos mesmos, que quando em contato com um fluido do corpo e/ou pela influência da temperatura do corpo, são transformados em um cristal líquido ou numa mistura de cristais líquidos, que funciona como uma matriz de liberação controlada para nicotina, adequado. Por exemplo, para a interrupção do ato de fumar e/ou terapias de substituição. As composições divulgadas dos ditos cristais líquidos ou dispersões dos mesmos, seus precursores ou descendentes dos mesmos, contendo nicotina ou antiirritantes ou um analgésico local, ou quaisquer combinações destes, reduzem a irritação local da nicotina e mascaram seu teste. As rotas aplicáveis de dispositivos e administração incluem administração bucal, usando goma de mascar em que cristais líquidos e dispersões dos mesmos ou precursores e descendentes dos mesmos são formulados, adesivos géis e emplastros bucais, usando cristal líquido adesivo de muco, dispersões dos mesmos ou precursores dos mesmos, e spray para boca usando dispersão dos ditos cristais líquidos, seus precursores ou descendentes , spray e gel nasal usando os ditos cristais líquidos ou suas dispersões, seus precursores ou descendentes, e uso tópico, usando o dito cristal líquido ou seus precursores ou descendentes em emplastros e géis adesivos.
BR9815395-1A 1997-09-25 1998-09-15 Composições à base de nicotina e método de formulção das mesmas BR9815395A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703458A SE9703458D0 (sv) 1997-09-25 1997-09-25 Nicotine compositions and methods of formulation thereof
PCT/SE1998/001632 WO1999015171A1 (en) 1997-09-25 1998-09-15 Nicotine compositions and methods of formulation thereof

Publications (1)

Publication Number Publication Date
BR9815395A true BR9815395A (pt) 2000-11-14

Family

ID=20408364

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815395-1A BR9815395A (pt) 1997-09-25 1998-09-15 Composições à base de nicotina e método de formulção das mesmas

Country Status (22)

Country Link
EP (1) EP1023069B1 (pt)
JP (1) JP2001517624A (pt)
KR (1) KR20010024305A (pt)
CN (1) CN1123343C (pt)
AT (1) ATE253362T1 (pt)
AU (1) AU733619B2 (pt)
BR (1) BR9815395A (pt)
CA (1) CA2304042A1 (pt)
DE (1) DE69819548T2 (pt)
DK (1) DK1023069T3 (pt)
EE (1) EE200000154A (pt)
ES (1) ES2210817T3 (pt)
FI (1) FI20000692A7 (pt)
HU (1) HUP0004802A3 (pt)
MX (1) MXPA00002955A (pt)
NO (1) NO20001540L (pt)
NZ (1) NZ503408A (pt)
PT (1) PT1023069E (pt)
RU (1) RU2201747C2 (pt)
SE (1) SE9703458D0 (pt)
WO (1) WO1999015171A1 (pt)
ZA (1) ZA988794B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
AT409219B (de) * 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln
KR100381622B1 (ko) * 2000-08-30 2003-04-26 디디에스텍주식회사 자극성을 줄인 염기성 약물의 구강 투여 조성물
DE10057769A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
SE0102197D0 (sv) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2003082240A1 (de) * 2002-03-30 2003-10-09 Beisel Guenther Zubereitung enthaltend fettsäure zur appetitminderung, sättigung und/oder gewichtsreduktion
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
KR100443722B1 (ko) * 2002-09-26 2004-08-09 이용원 니코틴을 함유한 하드츄잉캔디 및 그의 제조방법
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US8992974B2 (en) * 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US9498454B2 (en) * 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
RU2250052C2 (ru) * 2003-05-16 2005-04-20 Квасенков Олег Иванович Способ производства некурительного табачного изделия
RU2250051C2 (ru) * 2003-05-16 2005-04-20 Квасенков Олег Иванович Способ производства некурительного табачного изделия
RU2250057C2 (ru) * 2003-05-16 2005-04-20 Квасенков Олег Иванович Способ производства некурительного табачного изделия
TW200514579A (en) * 2003-07-24 2005-05-01 Smithkline Beecham Corp Orally dissolving films
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
WO2005046363A2 (en) 2003-11-07 2005-05-26 U.S. Smokeless Tobacco Company Tobacco compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
US20080219935A1 (en) * 2005-07-08 2008-09-11 Sang-Hoon Kwak Phase Transitive Breath Care Products
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CA2649149A1 (en) * 2006-04-11 2007-10-25 Koko Kosmetikvertrieb Gmbh & Co. Kg Nanoparticle containing nicotine and/or cotinine, dispersions, and use thereof
US20080287507A1 (en) * 2007-05-16 2008-11-20 John Hedenstrom Nicotine containing toiletry waters
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
GB2476471A (en) * 2009-12-22 2011-06-29 Norwich Pharma Technologies Ltd Cotinine formulation for the treatment of obesity
US8846725B2 (en) * 2011-01-24 2014-09-30 Quadex Pharmaceuticals, Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
CN102552405B (zh) * 2012-03-21 2013-10-16 张伟 一种肛周术后麻醉镇痛的药物组合物的制备方法
CN103040741B (zh) * 2012-12-11 2014-11-05 中山大学 溶致液晶的前体混悬液及其制备方法
WO2014135630A1 (en) * 2013-03-07 2014-09-12 Danmarks Tekniske Universitet Nano-microdelivery systems for oromucosal delivery of an active ingredient
KR102490695B1 (ko) * 2013-05-06 2023-01-19 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 염 제제 및 그 방법
WO2015090337A1 (en) * 2013-12-20 2015-06-25 Fertin Pharma A/S Nicotine powder composition
JP6672258B2 (ja) * 2014-04-08 2020-03-25 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン製剤及びその作製方法
GB201414919D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
CN108472251B (zh) * 2016-01-13 2022-02-01 株式会社 Lg 生活健康 口腔用制剂
CN108323791B (zh) * 2018-01-03 2021-02-12 云南中烟工业有限责任公司 一种尼古丁-氧化锌复合物、其制备方法及包含其的烟草制品
MX2020010908A (es) * 2018-04-16 2021-03-25 Poviva Corp Composiciones infundidas con compuestos de nicotina y metodos de uso de las mismas.
CN109125251B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 一种包载蛋白类药物的温敏性液晶凝胶制剂及其制备方法
KR102186704B1 (ko) * 2019-02-18 2020-12-04 (주)아이엠디팜 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication
LU101511B1 (en) * 2019-12-02 2021-06-04 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a parenteral administration and a process for the preparation of an injectable substance
US12137723B2 (en) 2019-12-09 2024-11-12 Nicoventures Trading Limited Oral products with active ingredient combinations
NL2031331B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of a short-acting psychedelic compound
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds
EP4570082A1 (en) * 2023-12-15 2025-06-18 Contraf-Nicotex-Tobacco GmbH Oral product for delivery of nicotine comprising a nicotine salt of a fatty acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
CA2120359C (en) * 1991-10-04 2000-12-26 Tomas Landh Particles, method of preparing said particles and uses thereof
EP0871489A1 (en) * 1995-10-12 1998-10-21 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface

Also Published As

Publication number Publication date
JP2001517624A (ja) 2001-10-09
ATE253362T1 (de) 2003-11-15
EE200000154A (et) 2001-02-15
FI20000692L (fi) 2000-03-24
ZA988794B (en) 1999-04-01
WO1999015171A1 (en) 1999-04-01
CN1278174A (zh) 2000-12-27
DE69819548D1 (de) 2003-12-11
AU733619B2 (en) 2001-05-17
HUP0004802A2 (hu) 2001-05-28
NZ503408A (en) 2004-12-24
EP1023069B1 (en) 2003-11-05
KR20010024305A (ko) 2001-03-26
SE9703458D0 (sv) 1997-09-25
ES2210817T3 (es) 2004-07-01
CA2304042A1 (en) 1999-04-01
AU9287298A (en) 1999-04-12
MXPA00002955A (es) 2002-04-24
EP1023069A1 (en) 2000-08-02
NO20001540L (no) 2000-05-25
PT1023069E (pt) 2004-02-27
DE69819548T2 (de) 2004-08-12
RU2201747C2 (ru) 2003-04-10
DK1023069T3 (da) 2004-03-08
CN1123343C (zh) 2003-10-08
FI20000692A7 (fi) 2000-03-24
NO20001540D0 (no) 2000-03-24
HUP0004802A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
BR9815395A (pt) Composições à base de nicotina e método de formulção das mesmas
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
AR063201A1 (es) Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas
BR0112356A (pt) Formulações farmacêuticas tópicas e métodos de tratamento
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
ATE138071T1 (de) Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
NO993777L (no) Fremgangsmaate for aa behandle sykdom omfattende törre öyne med purinergisk reseptor agonister
BR0114754A (pt) Compostos não-imidazóis
BR9814755A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos para a preparação de um composto, para inibir a secreção do ácido gástrico, para o tratamento de doenças inflamatórias gastrointestinais, e para o tratamento ou profilaxia de condições que envolvam infecção por helicobacter pylori da mucosa gástrica humana
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
ES2072447T3 (es) Locion analgesica externa y procedimiento de preparacion.
FI944123A0 (fi) Farmaseuttiset inhalaatiokoostumukset
BR0317349A (pt) Droga sólida para uso oral
ATE286733T1 (de) Abgabeverfahren und formulierungen für vaginalwirkstoffe
BR9807079A (pt) Composto de derivado de 16-hidróxi-11- (fenil substituìdo) - estra-4,9-dieno, uso de um composto, formulação farmacêutica, e processo para a preparação de um composto.
BR9902808A (pt) Compostos, composição farmacêutica, composição cosmética e uso de uma composição cosmética
BR0214141A (pt) Derivados de piperidina e seu uso como moduladores da atividade de receptor de quimiocina (especialmente ccr5)
WO2001068082A1 (en) Treatment and/or prevention of ocular pain
HUP9802553A2 (hu) Karbonanhidratáz inhibitorok alkalmazása a retina véráramának növelésére szolgáló gyógyszerkészítmények előállítására
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
AR018347A1 (es) 1h-indazoles 1,5 y 3-o-sustituidos y sus sales fisiologicamente tolerables, utilizacion de los mismos para la preparacion de medicamentos, procedimientospara preparar dichos compuestos, las composiciones y preparaciones farmaceuticas que los contienen, y la utilizacion de dichos compuestos y prepara
UHDE The problem of permeability and anesthesia of the tympanic membrane
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.